Pulmonary surfactant for neonatal respiratory disorders

Area of Science:

• Neonatal medicine
• Pulmonology
• Biochemistry

Background:

• Surfactant therapy significantly improves outcomes for preterm infants with respiratory distress syndrome.
• Surfactant-associated proteins play crucial roles in lung function and immune defense.
• Evolving neonatal care practices, like increased use of nasal continuous positive airway pressure, raise questions about optimal surfactant therapy timing.

Purpose of the Study:

• To review the current understanding of surfactant therapy in neonatal respiratory disorders.
• To discuss the challenges and potential future directions for exogenous surfactant use.
• To explore the role of surfactant dysfunction in conditions beyond the immediate neonatal period.

Main Methods:

• Literature review of studies on surfactant therapy in neonates.
• Analysis of surfactant function, protein roles, and immune defense mechanisms.
• Examination of evidence for surfactant therapy in various neonatal respiratory conditions.

Main Results:

• Optimal timing for exogenous surfactant administration, especially with non-invasive ventilation, requires further study.
• Surfactant dysfunction is observed in preterm infants with bronchopulmonary dysplasia and prolonged ventilation, but therapy beyond the first week is understudied.
• Current commercial surfactant preparations have limitations due to protein variability and inhibition susceptibility.

Conclusions:

• Further research is needed to establish optimal surfactant therapy protocols for evolving neonatal respiratory support strategies.
• Development of novel, improved "designer" surfactant preparations is a promising avenue for advancing treatment of neonatal respiratory disorders.
• Understanding surfactant-associated proteins is key to enhancing both respiratory and immune functions in neonates.